Sanofi SA has announced plans to pay $11.6 billion to acquire Bioverativ Inc of Waltham, Massachusetts, US in order to enhance its position in specialty care. Bioverativ has two marketed products for haemophilia A and B. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
